These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 34283349)

  • 1. Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo.
    Wang Y; Li S; Li C
    Clin Rev Allergy Immunol; 2021 Dec; 61(3):299-323. PubMed ID: 34283349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy.
    Boniface K; Seneschal J; Picardo M; Taïeb A
    Clin Rev Allergy Immunol; 2018 Feb; 54(1):52-67. PubMed ID: 28685247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The enigma and challenges of vitiligo pathophysiology and treatment.
    Abdel-Malek ZA; Jordan C; Ho T; Upadhyay PR; Fleischer A; Hamzavi I
    Pigment Cell Melanoma Res; 2020 Nov; 33(6):778-787. PubMed ID: 32198977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights into immune mechanisms of vitiligo.
    Boniface K; Taïeb A; Seneschal J
    G Ital Dermatol Venereol; 2016 Feb; 151(1):44-54. PubMed ID: 26512930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innate immune mechanisms in vitiligo: danger from within.
    Richmond JM; Frisoli ML; Harris JE
    Curr Opin Immunol; 2013 Dec; 25(6):676-82. PubMed ID: 24238922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitiligo: Mechanistic insights lead to novel treatments.
    Frisoli ML; Harris JE
    J Allergy Clin Immunol; 2017 Sep; 140(3):654-662. PubMed ID: 28778794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitiligo: From Pathogenesis to Treatment.
    Speeckaert R; Caelenberg EV; Belpaire A; Speeckaert MM; Geel NV
    J Clin Med; 2024 Sep; 13(17):. PubMed ID: 39274437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding mechanisms of autoimmunity through translational research in vitiligo.
    Strassner JP; Harris JE
    Curr Opin Immunol; 2016 Dec; 43():81-88. PubMed ID: 27764715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on Vitiligo pathogenesis.
    Seneschal J; Boniface K; D'Arino A; Picardo M
    Pigment Cell Melanoma Res; 2021 Mar; 34(2):236-243. PubMed ID: 33278065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant HSP70 reverses autoimmune depigmentation in vitiligo.
    Mosenson JA; Zloza A; Nieland JD; Garrett-Mayer E; Eby JM; Huelsmann EJ; Kumar P; Denman CJ; Lacek AT; Kohlhapp FJ; Alamiri A; Hughes T; Bines SD; Kaufman HL; Overbeck A; Mehrotra S; Hernandez C; Nishimura MI; Guevara-Patino JA; Le Poole IC
    Sci Transl Med; 2013 Feb; 5(174):174ra28. PubMed ID: 23447019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Innate Immunity to Combat Cutaneous Stress: The Vitiligo Perspective.
    Boniface K; Passeron T; Seneschal J; Tulic MK
    Front Immunol; 2021; 12():613056. PubMed ID: 33936032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Concepts of Vitiligo Immunopathogenesis.
    Hlača N; Žagar T; Kaštelan M; Brajac I; Prpić-Massari L
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patho-immunological mechanisms of vitiligo: the role of the innate and adaptive immunities and environmental stress factors.
    Faraj S; Kemp EH; Gawkrodger DJ
    Clin Exp Immunol; 2022 Jan; 207(1):27-43. PubMed ID: 35020865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment update for vitiligo based on autoimmune inhibition and melanocyte protection.
    Xie B; Zhu Y; Shen Y; Xu W; Song X
    Expert Opin Ther Targets; 2023 Mar; 27(3):189-206. PubMed ID: 36947026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitiligo Pathogenesis and Emerging Treatments.
    Rashighi M; Harris JE
    Dermatol Clin; 2017 Apr; 35(2):257-265. PubMed ID: 28317534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitiligo: A focus on pathogenesis and its therapeutic implications.
    Bergqvist C; Ezzedine K
    J Dermatol; 2021 Mar; 48(3):252-270. PubMed ID: 33404102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo.
    Boukhedouni N; Martins C; Darrigade AS; Drullion C; Rambert J; Barrault C; Garnier J; Jacquemin C; Thiolat D; Lucchese F; Morel F; Ezzedine K; Taieb A; Bernard FX; Seneschal J; Boniface K
    JCI Insight; 2020 Jun; 5(11):. PubMed ID: 32369451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-and-Coming Drugs for the Treatment of Vitiligo.
    Seong SH; Oh SH
    Ann Dermatol; 2024 Aug; 36(4):197-208. PubMed ID: 39082655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
    Liu LY; Strassner JP; Refat MA; Harris JE; King BA
    J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the elevated IFN-γ in vitiligo patients by human anti- IFN-γ monoclonal antibody hampers direct cytotoxicity in melanocyte.
    Ng CY; Chan YP; Chiu YC; Shih HP; Lin YN; Chung PH; Huang JY; Chen HK; Chung WH; Ku CL
    J Dermatol Sci; 2023 Jun; 110(3):78-88. PubMed ID: 37221109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.